Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand
Authors: S. Migasena
D. G. Heppner
D. E. Kyle
T. Chongsuphajaisiddhi
D. M. Gordon
P. Suntharasamai
B. Permpanich
A. Brockman
P. Pitiuttutham
C. Wongsrichanalai
P. Srisuriya
B. Phonrat
K. Pavanand
C. Viravan
W. R. Ballou
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Walter Reed Army Institute of Research
Shoklo Malaria Research Unit
Keywords: Immunology and Microbiology;Medicine
Issue Date: 30-Sep-1997
Citation: Acta Tropica. Vol.67, No.3 (1997), 215-227
Abstract: In preparation for an efficacy trial of malaria vaccine SPf66 in Thailand, a series of overlapping Phase I trials were conducted of US- manufactured SPf66. Here, two clinical lots were evaluated for safety and immunogenicity in a combined open-label trial. Eleven healthy, malaria naive, 18-44 year-old Thai men and women received three doses by subcutaneous injection in alternate arms at 0, 1 and 6 months. Safety was assessed by monitoring local and systemic reactogenicity and laboratory parameters. Common side effects were mild erythema, induration and tenderness at the site of injection which resolved within 24-48 h. At third immunization, two volunteers developed acute bilateral reactions with induration, erythema and pruritus limited to the sites of the second and third immunizations. Eight of 11 volunteers sero-converted by ELISA, six of whom would be classified as high responders by Colombian standards. Eight of 11 volunteers developed a lymphoproliferative response to the SPf66 antigen. Side effects were more common and antibody and lymphoproliferative responses greatest, among the four female volunteers. This initial study of SPf66 malaria vaccine in Asia constitutes an essential link between the initial Phase I study in the US and subsequent field studies in a semi-immune population in a malaria endemic area of Thailand. This study further establishes comparability of US- manufactured SPf66 with that of Colombian provenance and substantiates the validity of the subsequent negative efficacy results of SPf66 in a field trial in Thailand.
ISSN: 0001706X
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.